Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks?

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Cheap Quarterly Dividend Stocks to Buy Right Now.

Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks?

Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company, offers investors a strong and diverse portfolio. It has more than two dozen brands, including several blockbuster drugs that each bring in over $1 billion in annual sales.

Amgen Inc. (NASDAQ:AMGN)’s medicines span multiple therapeutic areas. These include Repatha, which lowers the risk of heart attacks in certain patients; Evenity and Prolia, used for bone health in postmenopausal women and cancer patients; and Otezla, a treatment for plaque psoriasis.

This broad lineup supports steady revenue and earnings growth. In the second quarter, Amgen Inc. (NASDAQ:AMGN) reported revenue of $9.2 billion, up 9% from the prior year, while adjusted earnings per share rose 21% to $6.02. The company is also a solid dividend pick with 14 consecutive years of dividend growth under its belt. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.32%, as of September 23.

While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Safest Monthly Dividend Stocks to Buy and Dividend Stock Portfolio For Retirement: 10 Stocks to Buy

Disclosure: None.